MedTrace Logo

Chronic, Low Dose Erythropoetin Beta in Ischemic Cardiomyopathy

NCT00568542 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2009-08-04

No results posted yet for this study

Summary

The study is testing the hypothesis, that the application of low dose erythropoetin beta (35 I.E./kg BW/week) for 6 months following successful coronary revascularization by PCI improves left ventricular remodeling as assessed by cardiac MRI.

Conditions

  • Ischemic Cardiomyopathy

Interventions

DRUG

erythropoetin beta

35 I.E. kg body weight subcutaneous once per week for 6 months

DRUG

placebo

35 I.E. kg body weight placebo to erythropoetin beta

Sponsors & Collaborators

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Martin W Bergmann, MD · Charité Camous Buch, University Medicine Berlin, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00568542 on ClinicalTrials.gov